₹553.40
+0.28%NSE close, 16 Nov 2026
−12.54%
Astec LifeSciences is a small cap company, listed on NSE under the symbol ASTEC. At ₹553.40 a share, the market values the whole company at ₹1,233 crore.
In FY26, it reported sales of ₹448 crore and a net loss of ₹81 crore, an operating margin of -1.0%. Over the last three years, sales fell 12.8% a year.
The market values the company at 3.68 times its book value; its return on equity is -23.8% and its borrowings are 0.99 times its equity.
Promoters hold 71.96% of the shares. Foreign institutions hold 0.03%, and domestic institutions, mutual funds among them, 3.34%.
Over the past year the share price has fallen 14.1%, and it is 41.2% below its 52-week high.
₹ crore. Consolidated figures.
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Outcome of Board Meeting held on October 26, 2026.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 50.8 | 154 | 69.4 | 98.6 | 93.9 | 120 | 91.1 | 73.7 | 125 | 159 | 83.6 | 72.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 69.1 | 141 | 116 | 118 | 99.6 | 114 | 102 | 80.4 | 121 | 149 | 84.2 | 91.8 |
| Operating profit | −18.3 | 12.7 | −46.3 | −19.7 | −5.7 | 5.5 | −11.0 | −6.7 | 4.0 | 9.2 | −0.7 | −19.8 |
| Operating margin | -36.1% | 8.3% | -66.7% | -20.0% | -6.1% | 4.6% | -12.1% | -9.1% | 3.2% | 5.8% | -0.8% | -27.5% |
| Other income | 0.9 | 2.1 | 0.9 | 2.0 | 1.9 | 0.8 | 0.5 | 1.1 | 0.8 | 2.6 | 0.7 | 0.6 |
| Interest | 6.1 | 6.7 | 7.0 | 9.3 | 9.9 | 10.4 | 11.0 | 8.4 | 7.2 | 7.9 | 7.7 | 7.1 |
| Depreciation | 8.7 | 9.0 | 9.3 | 11.5 | 11.4 | 11.6 | 11.5 | 10.4 | 11.2 | 11.8 | 11.1 | 11.2 |
| Profit before tax | −32.2 | −0.9 | −61.6 | −38.5 | −25.2 | −15.7 | −33.0 | −24.4 | −15.7 | −7.9 | −18.7 | −37.4 |
| Tax | −7.9 | 0.0 | −21.9 | 0.0 | 15.2 | 0.4 | 0.0 | 0.0 | 0.0 | −0.2 | −0.0 | −0.0 |
| Net profit | −24.3 | – | −39.7 | −38.6 | −40.4 | −16.1 | −33.0 | −24.4 | −15.7 | −7.8 | −18.7 | −37.4 |
| EPS (₹) | -12.41 | – | -20.26 | -19.66 | -20.59 | -8.20 | -16.85 | -11.35 | -7.04 | -3.48 | -8.40 | -16.79 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Sales | 431 | 523 | 555 | 677 | 458 | 381 | 448 |
| Expenses | 354 | 437 | 443 | 523 | 464 | 448 | 453 |
| Operating profit | 76.5 | 85.2 | 112 | 154 | −5.9 | −66.2 | −4.5 |
| Operating margin | 17.7% | 16.3% | 20.1% | 22.8% | -1.3% | -17.4% | -1.0% |
| Other income | 11.2 | 11.9 | 7.9 | 10.5 | 5.7 | 5.6 | 5.1 |
| Interest | 12.4 | 12.6 | 4.8 | 9.1 | 25.2 | 36.7 | 34.5 |
| Depreciation | 19.4 | 23.2 | 25.7 | 34.4 | 36.3 | 43.7 | 44.9 |
| Profit before tax | 55.9 | 61.4 | 89.1 | 121 | −61.8 | −141 | −81.0 |
| Tax | 20.1 | 13.8 | 24.0 | 31.2 | −14.9 | −6.3 | −0.1 |
| Net profit | 35.7 | 47.5 | 65.1 | 89.9 | −46.9 | −135 | −80.9 |
| EPS (₹) | 18.28 | 24.29 | 33.23 | 45.87 | -22.94 | -68.71 | -37.79 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 23.6 | −8.4 | −80.7 | 122 |
| From investing | −104 | −15.2 | −4.3 | −0.5 |
| From financing | 80.5 | 23.7 | 94.5 | −131 |
| Spent on fixed assets | −104 | −21.8 | −5.5 | −1.8 |
| Free cash flow | −80.4 | −30.2 | −86.3 | 120 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 8.3% | 9.1% | 11.7% | 13.3% | -10.2% | -35.3% | -18.1% |
| Operating margin | 17.7% | 16.3% | 20.1% | 22.8% | -1.3% | -17.4% | -1.0% |
| Return on equity | – | – | – | – | -12.7% | -57.4% | -20.7% |
| Return on capital employed | – | – | – | – | -4.2% | -13.2% | -5.5% |
| Return on assets | – | – | – | – | -4.8% | -15.3% | -8.6% |
| Debt to equity | – | – | – | – | 1.34 | 2.36 | 1.15 |
| Interest coverage | 5.50 | 5.90 | 19.80 | 14.40 | -1.40 | -2.80 | -1.30 |
| Debt to assets | – | – | – | – | 0.51 | 0.63 | 0.48 |
| Current ratio | – | – | – | – | 1.00 | 0.93 | 0.89 |
| Quick ratio | – | – | – | – | 0.51 | 0.50 | 0.61 |
| Cash ratio | – | – | – | – | 0.00 | 0.00 | 0.02 |
| Asset turnover | – | – | – | – | 0.47 | 0.43 | 0.48 |
| Fixed asset turnover | – | – | – | – | 1.30 | 0.77 | 1.06 |
| Inventory turnover | – | – | – | – | 1.60 | 1.90 | 2.20 |
| Receivables turnover | – | – | – | – | 2.70 | 2.60 | 1.80 |
| Gross margin | – | – | – | – | 30.3% | 22.1% | 33.4% |
| Cash from operations to profit | – | – | – | 26.0% | – | – | – |
| Effective tax rate | 36.0% | 22.5% | 26.9% | 25.8% | – | – | – |
The unaudited financial results for the quarter and half year ended September 30, 2026.
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Significant movement in price has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant movement in price has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Adoption of Annual Report 2025-26 by the Shareholders at the AGM held on 31st July, 2026.